Main results
At baseline, 2786 patients (15%) had paroxysmal AF, and 15 412 (85%) had persistent or permanent AF. Median duration of AF was 840 days. Apixaban reduced stroke or systemic embolism, major bleeding, and all-cause mortality more than warfarin regardless of type (P for interactions > 0.50) (Table) or duration of AF (P for interactions > 0.13).
Conclusion
In patients with atrial fibrillation (AF), apixaban reduced stroke or systemic embolism more than warfarin regardless of type or duration of AF. 
*

Commentary
In this prespecified secondary analysis of the ARISTOTLE trial, Al-Khatib and colleagues report that apixaban consistently provided a greater net clinical benefit than warfarin in patients with AF, regardless of AF type (paroxysmal vs permanent) or duration, although confidence intervals were wide for patients with paroxysmal AF. This supports the emerging role of apixaban, a new oral anticoagulant (NOAC) that inhibits factor Xa, as a preferred agent for carefully selected patients with AF and ≥ 1 stroke risk factor. When prescribing NOACs, we should consider that some patients with AF may not be good candidates, such as those with a prosthetic valve, mitral valve stenosis, advanced renal failure (creatinine clearance < 30 mL/min), or inability to afford medication. Aspirin may be more appropriate for patients with AF and a CHADS 2 score of 0, depending on the presence of other vascular risk factors (1). Although routine laboratory monitoring is not necessary with NOACs, recent guidelines recommend periodic screening for renal and hepatic function, bleeding risk assessment, interacting medications, and periprocedural planning (2). Whereas there are no head-to-head comparisons of the 3 NOACs approved by the US Food and Drug Administration (apixaban, rivaroxaban, and dabigatran), differences in patient characteristics and pharmacokinetic/pharmacodynamic profiles may influence our choice of agent. Other considerations include patient adherence to once-or twice-daily dosing, risk for gastrointestinal bleeding, degree of renal or hepatic drug elimination, and efficacy and safety outcomes as demonstrated in clinical trials.
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